<DOC>
	<DOCNO>NCT00077207</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin , vincristine , temozolomide , work different way stop tumor cell divide stop grow die . Giving one drug may kill tumor cell . PURPOSE : This pilot study study give carboplatin vincristine together temozolomide treat child progressive and/or symptomatic low-grade glioma .</brief_summary>
	<brief_title>Carboplatin , Vincristine , Temozolomide Treating Children With Progressive and/or Symptomatic Low-Grade Glioma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility toxicity induction maintenance regimen comprise carboplatin , vincristine , temozolomide child progressive and/or symptomatic low-grade glioma . Secondary - Determine response rate patient treat regimen . - Determine 3-year progression-free survival overall survival patient treat regimen . - Correlate response progression-free survival genomic profile tumor patient treat regimen . OUTLINE : This pilot study . - Induction therapy : Patients receive carboplatin IV 1 hour day 1 , 8 , 15 , 22 ; vincristine IV day 1 , 8 , 15 , 22 , 29 , 36 ; oral temozolomide day 43-47 . Four week completion induction therapy , patient achieve stable respond disease proceed maintenance therapy . - Maintenance therapy : Patients receive carboplatin temozolomide induction therapy vincristine IV day 1 , 8 , 15 . Treatment repeat every 10 week total 6 course absence disease progression . Patients follow every 3 month 1 year , every 4 month 1 year , every 6 month 1 year , annually thereafter . PROJECTED ACCRUAL : A total 30-50 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm progressive and/or symptomatic lowgrade glioma , include follow : WHO grade I II astrocytoma Grade I II oligodendrogliomas Mixed oligodendrogliomas Gangliogliomas Measurable disease Progressive and/or symptomatic supratentorial spinal cord tumor remove anatomical reason allow Optic pathway tumor allow provided evidence progressive disease MRI and/or symptom deteriorate vision , progressive hypothalamic/pituitary dysfunction , diencephalic syndrome Dorsally exophytic brainstem gliomas previously resect 50 % allow provide residual tumor show progression ( without symptom ) No diffuse brain stem tumors No type 1 neurofibromatosis PATIENT CHARACTERISTICS : Age 10 Performance status ECOG 02 Lansky 50100 % Life expectancy Not specify Hematopoietic Hemoglobin ≥ 8.0 gm/dL Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT &lt; 2.5 time ULN Renal Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR Creatinine ≤ 0.8 mg/dL ( age 5 ) OR ≤ 1.0 mg/dL ( age 6 to10 ) Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 2 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunomodulating agent Chemotherapy No concurrent anticancer chemotherapy Endocrine therapy Prior corticosteroid allow No concurrent corticosteroid except treatment increase intracranial pressure Radiotherapy Not specify Surgery See Disease Characteristics Prior surgery allow Other No prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>untreated childhood cerebellar astrocytoma</keyword>
	<keyword>untreated childhood visual pathway hypothalamic glioma</keyword>
	<keyword>childhood spinal cord neoplasm</keyword>
	<keyword>childhood oligodendroglioma</keyword>
	<keyword>childhood low-grade cerebral astrocytoma</keyword>
</DOC>